Dynamic Risk Stratification for Predicting Treatment Response in Differentiated Thyroid Cancer

被引:7
|
作者
Giannoula, Evanthia [1 ]
Melidis, Christos [2 ]
Papadopoulos, Nikitas [3 ]
Bamidis, Panagiotis [4 ]
Raftopoulos, Vasilios [5 ]
Iakovou, Ioannis [1 ]
机构
[1] Aristotle Univ Thessaloniki, Acad Gen Hosp Thessaloniki AHEPA, Acad Nucl Med Dept 2, Kiriakidi 1 St, Thessaloniki 54621, Greece
[2] CAP Sante, Radiat Therapy Dept, 13 Rue Marcel Paul, F-20200 Bastia, France
[3] Gen Hosp Thessaloniki Georgios Gennimatas, Ethnikis Aminis 41 St, Thessaloniki 54635, Greece
[4] Aristotle Univ Thessaloniki, Med Sch, Med Phys Lab, Thessaloniki 54635, Greece
[5] Natl Publ Hlth Org EODY, Div HIV AIDS Epidemiol Surveillance, Agrafon 3-5 St, Athens 15123, Greece
关键词
thyroid cancer; dynamic risk stratification; treatment response; prognostic factors; STIMULATED THYROGLOBULIN; PROGNOSTIC-FACTORS; PAPILLARY; ASSOCIATION; GUIDELINES; CARCINOMA; ABLATION; RECURRENCE; EXTENSION; SURVIVAL;
D O I
10.3390/jcm9092708
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prognosis in Differentiated Thyroid Cancer (DTC) patients is excellent, but a significant degree of overtreatment still exists because of the inability to accurately identify small patient cohorts who experience a more aggressive form of the disease, often associated with certain poor prognostic factors. Identifying these cohorts at an early stage would allow patients at high risk to receive more aggressive treatment while avoiding unnecessary and invasive treatments in those at low risk. Most risk stratification systems include age, tumor size, grade, presence of local invasion, and regional or distant metastases. Here we discuss these common factors as well as their association with treatment response, but also other upcoming markers including histology and multifocality of primary tumor, dose administered and preparation method for Radioiodine Therapy (RAI), Thyroglobulin (Tg), Anti-thyroglobulin Antibodies (Tg-Ab) levels both at initial management and during follow-up, and the presence of previously existing benign thyroid disease. In addition, we examine the role of remnant size and avidity as well as surgeons' experience in performing thyroidectomies with recurrence rate, discussing its impact on disease prognosis. Our results reveal that treatment response has a statistically significant association with histology, T and M stages, surgeons' experience, Tg levels and remnant score both during RAI and follow up and Tg-Ab levels during follow-up whole body scan (WBS).
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [21] Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah
    Jasim, Mahmod S.
    Hussein, Ibrahim H.
    Alidrisi, Haider A.
    Mansour, Abbas A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [22] Dynamic Risk Stratification Integrated with ATA Risk System for Predicting Long-Term Outcome in Papillary Thyroid Cancer
    Valerio, Laura
    Dalmiglio, Cristina
    Maino, Fabio
    Mattii, Elisa
    Trimarchi, Andrea
    Cartocci, Alessandra
    Castagna, Maria Grazia
    CANCERS, 2023, 15 (18)
  • [23] The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old
    Senyurek, Yasemin Giles
    Iscan, Yalin
    Sormaz, Ismail Cem
    Poyrazoglu, Sukran
    Tunca, Fatih
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2022, 14 (02) : 196 - 206
  • [24] The role of the size in thyroid cancer risk stratification
    Vianello, Federica
    Censi, Simona
    Watutantrige-Fernando, Sara
    Barollo, Susi
    Zhu, Yi Hang
    Albiger, Nora
    Bertazza, Loris
    Manso, Jacopo
    Carducci, Sofia
    Benna, Clara
    Iacobone, Maurizio
    Galuppini, Francesca
    Pennelli, Gianmaria
    Mian, Caterina
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [25] Long term outcomes of simple clinical risk stratification in management of differentiated thyroid cancer
    Craig, W. L.
    Smart, L.
    Fielding, S.
    Ramsay, C.
    Krukowski, Z. H.
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2018, 16 (05): : 283 - 291
  • [26] Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
    Abelleira, Erika
    Angela Penaloza, Mirna
    Jerkovich, Fernando
    Bueno, Fernanda
    Pitoia, Fabian
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2021, 65 (03): : 315 - 321
  • [27] Thyroid hormone therapy in differentiated thyroid cancer
    Grani, Giorgio
    Ramundo, Valeria
    Verrienti, Antonella
    Sponziello, Marialuisa
    Durante, Cosimo
    ENDOCRINE, 2019, 66 (01) : 43 - 50
  • [28] Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer
    Bandeira, Leonardo
    Padovani, Rosalia do Prado
    Ticly, Ana Luiza
    Cury, Adriano Namo
    Scalissi, Nilza Maria
    Silveira Marone, Marilia Martins
    Ferraz, Carolina
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2017, 61 (06): : 590 - 599
  • [29] An impact of microscopic positive margin on incomplete response after I-131 treatment in differentiated thyroid cancer
    Raruenrom, Yutapong
    Sawangsri, Katanyoo
    Somboonporn, Charoonsak
    Theerakulpisut, Daris
    Wongsurawat, Nantaporn
    Ratanaanekchai, Teeraporn
    ANNALS OF NUCLEAR MEDICINE, 2020, 34 (07) : 453 - 459
  • [30] Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma
    Jeon, Min Ji
    Kim, Won Gu
    Park, Woo Ri
    Han, Ji Min
    Kim, Tae Yong
    Song, Dong Eun
    Chung, Ki-Wook
    Ryu, Jin-Sook
    Hong, Suck Joon
    Shong, Young Kee
    Kim, Won Bae
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 170 (01) : 23 - 30